 Arrowhead Pharmaceuticals Inc NASDAQ: ARWR has announced positive interim 48-week liver biopsy results from the Phase 2 AROAAT2002 study evaluating ARO-AAT for rare genetic liver disease associated with alpha-1 antitrypsin deficiency AATD. AATD is the lack of a protein made by the liver released into the bloodstream. 